Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

Showing results for "early lung health"

Research

among children with pneumonia using a causal Bayesian network

Pneumonia remains a leading cause of hospitalization and death among young children worldwide, and the diagnostic challenge of differentiating bacterial from non-bacterial pneumonia is the main driver of antibiotic use for treating pneumonia in children. Causal Bayesian networks (BNs) serve as powerful tools for this problem as they provide clear maps of probabilistic relationships between variables and produce results in an explainable way by incorporating both domain expert knowledge and numerical data.

Our stories of support

The The Kids Community stretches far and wide, and is full of inspiring people, doing inspiring things for child health research.

Research

Reversible Control by Vitamin D of Granulocytes and Bacteria in the Lungs of Mice: An Ovalbumin-Induced Model of Allergic Airway Disease

Vitamin D may be essential for restricting the development and severity of allergic diseases and asthma, but a direct causal link between vitamin D...

RHD Endgame tantalisingly close

Professor Jonathan Carapetis has made eliminating rheumatic heart disease his life’s work.

Impact: In the Pipeline

On this Research Impact page, we list stories helping to show our exciting in-progress research currently "in the pipeline" towards translation. This is research which shows a real spark of potential to make a significant difference to children and families worldwide.

News & Events

Research to explore promising new RSV treatment supported by innovation seed funding

Researchers from the Wal-yan Respiratory Research Centre are collaborating with Virex Pharma to undertake vital research into a potential breakthrough treatment for RSV infections in young children, thanks to a $499,241 grant awarded by the WA Department of Health Innovation Seed Fund.

Research

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.

Celebrating 10 Years of the Wesfarmers Centre

A decade long partnership with Wesfarmers Ltd. and the Wesfarmers Centre of Vaccines and Infectious Diseases has led to world-class paediatric research and important collaborations fuelling the Centre’s trajectory towards easing the burden of infectious diseases.

Research

Determining the off-target effects of infant vaccines on respiratory infection outcomes in Western Australian children

Christopher Hannah Lea-Ann Blyth Moore Kirkham MBBS (Hons) DCH FRACP FRCPA PhD OAM BSc (Hons) GradDipClinEpi PhD PhD Centre Head, Wesfarmers Centre

Geospatial Health and Development

Our Geospatial Health and Development Team uses cutting-edge technologies to better understand how and why the health and wellbeing of children varies from place to place. We develop innovative geospatial methods that can harness large, complex datasets to pinpoint hotspots of elevated risk, evaluate change through time, and explore underlying drivers.